AHSG Thr256Ser Gene Polymorphism as a Predictor of Low Serum Fetuin-A Levels in Indonesian Maintenance Hemodialysis Patients
DOI:
https://doi.org/10.3889/oamjms.2020.3520Keywords:
AHSG Thr256Ser gene polymorphism, Fetuin-A, HemodialysisAbstract
BACKGROUND: Vascular calcification (VC) is a risk factor for cardiovascular morbidity and mortality in maintenance hemodialysis (MHD) patients. The effect of alpha2-Heremans Schmid glycoprotein (AHSG) Thr256Ser gene polymorphism toward serum fetuin-A levels as one of the VC inhibitors in MHD patients is still unclear.
OBJECTIVE: This study aims to investigate the relationship between AHSG Thr256Ser gene polymorphism toward serum fetuin-A levels in MHD patients in Indonesia.
METHODS: The research study design used was cross-sectional. Serum fetuin-A levels were assessed by enzyme-linked immunosorbent assay method, and polymerase chain reaction-restriction fragment length polymorphism determined AHSG Thr256Ser gene polymorphism. Multivariate linear regression analysis was used to analyze the factors related to serum fetuin-A levels. p < 0.05 was considered as statistically significant.
RESULTS: Median value of serum fetuin-A levels was 235.0 pg/ml (ranging 78–756) with mean 259.99 ± 119.36 pg/ml. Out of 106 patients involved, the distribution of AHSG Thr256Ser genotype frequency was 54 (50.9%) respondents had CG genotype, 46.2% had CC genotype, and the others (2.8%) had GG genotype. Patients with homozygous C allele (CC genotype) were 0.1 times more protected (CI 95%: 0.1–0.3) to have low serum fetuin-A levels, compared with patients with G allele either in a homozygote (GG genotype) or in the heterozygote (CG genotype). From the multivariate analysis results, it can be obtained a formulation in predicting serum fetuin-A level, which is: Serum fetuin-A level prediction = 276,59 + 150,49 DM - 0,26 serum interleukin -6 level - 43,58 AHSG Thr256Ser gene polymorphism
CONCLUSIONS: AHSG Thr256Ser gene polymorphism had a significant relationship with serum fetuin-A levels in MHD patients in Indonesia. Subjects with G allele (CG and GG genotypes) had lower serum fetuin-A levels than those with CC genotype.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Cozzolino M, Mangano M, Stucchi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33 Suppl 3:iii28- 34. https://doi.org/10.1093/ndt/gfy174 PMid:30281132
Maharem DA, Gomaa SH, Gandhi MK, Mohamed EI. Association of serum fetuin-a and fetuin-a gene polymorphism in relation to mineral and bone disorders in patients with chronic kidney disease. Egyp J Med Hum Genet. 2013;14(4):337-52. https:// doi.org/10.1016/j.ejmhg.2013.07.003
Altuntas A, Yigit A, Uz E, Inal S. The relationship between fetuin levels and fetuin gene polymorphism in a hemodialysis patient. Biomed India. 2017;28(2):495-5. https://doi.org/10.1093/ndt/ gfv199.29
Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits- Filho R, Gao P, et al. Low fetuin-a levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005;67(6):2383-92. https://doi. org/10.1111/j.1523-1755.2005.00345.x PMid:15882283
Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimbürger O, Bárány P. Is fetuin-a/alpha2-heremans-schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? Am J Nephrol. 2008;28(4):669-76. https://doi. org/10.1159/000121358 PMid:18337634
Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001;12(11):2511-6. PMid:11675430
Zeidan MA, Sharara GM, Suliman HS, Zeid MM, Zytoun SS, Nomeir HM. Visfatin and fetuin-a: Novel markers for endothelial dysfunction in chronic kidney disease. Life Sci J. 2012;9(2):227-43.
Jensen KM, Jensen RA, Mukamal KJ. Detection of genetic loci associated with plasma fetuin-a: A meta-analysis of genome-wide association studies from the CHARGE consortium. Hum Mol Genet. 2017;26(11):2156-63. PMid:28379451
Verduijn M, Prein RA, Stenvinkel P, Carrero JJ, le Cessie S, Witasp A, et al. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. Nephrol Dial Transplant. 2011;26(1):239-45. https:// doi.org/10.1093/ndt/gfq402 PMid:20605840
Trepanowski JF, Mey J, Varady KA. Fetuin-a: A novel link between obesity and related complications. Int J Obes (Lond). 2015;39(5):734-41. https://doi.org/10.1038/ijo.2014.203 PMid:25468829
Celebi G, Genc H, Gurel H, Sertoglu E, Kara M, Tapan S, et al. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol. 2015;21(3):139-45. https://doi.org/10.4103/1319-3767.157556 PMid:26021772
Sindhu S. Fetuin an (AHSG) in metabolic and inflammatory diseases: A foe or a friend. Diabetes Obes Int J. 2015;1(5):127. https://doi.org/10.23880/doij-16000127
Oikawa O, Higuchi T, Yamazaki T. Evaluation of serum fetuin-a relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007;11(4):304-8. https://doi. org/10.1007/s10157-007-0499-y PMid:18085392
Ann A, Makkar V, Mann S, Ghamija P, Soundrajan P. Fetuin-a and vascular calcification in Indian end-stage renal disease population. Indian J Nephrol. 2016;26(1):33-8. https://doi. org/10.4103/0971-4065.157007 PMid:26937076
Yamada S, Tokumoto M, Tsuruya K. Fetuin-a induced by low protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. Am J Physiol Renal Physiol. 2015;309(8):F744-54. https://doi.org/10.1152/ ajprenal.00017.2015 PMid:26180236
Downloads
Published
How to Cite
License
Copyright (c) 2020 Riri Andri Muzasti, Suhardjono Suhardjono, M. B. Purwanto, R. J. Sembiring (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
